Helix BioPharma Corp. Announces Extension of 2009 Warrant Expiry Date
* Reuters is not responsible for the content in this press release.
Marketwire Helix BioPharma Corp. March 7, 2013 - 05:05:22 PM Helix BioPharma Corp. Announces Extension of 2009 Warrant Expiry Date AURORA, ON--(Marketwire - March 07, 2013) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it received the Toronto Stock Exchange's approval of its proposal to extend the expiry date of the 2009 Warrants (as defined below) by six months, from 5:00 p.m. Toronto time today until September 7, 2013 at 5:00 p.m. Therefore, effective as of 5:00 p.m. today, the expiry date of the 2009 Warrants was extended until September 7, 2013 at 5:00 p.m. No other provision of the 2009 Warrants has been amended, and none of the 2009 Warrants is held directly or indirectly by an insider of Helix. The 2009 Warrants were issued as part of a private placement completed by Helix on September 8, 2009, pursuant to which Helix issued 6,625,000 units at a subscription price of $2.05 per unit. Each unit consisted of one common share and one common share purchase warrant (each a "2009 Warrant"), with each 2009 Warrant common entitling the holder to purchase, subject to adjustment, one common share at a price of $2.87 until the Current Expiry Date. About Helix BioPharma Corp. Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP". Forward-Looking Statements and Risks and Uncertainties This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements, which may be identified by words including, without limitation, "will" and other similar expressions, are intended to provide information about management's current plans and expectations regarding future operations. Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, those described in Helix's Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed with the Canadian Securities Administrators at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law. FOR FURTHER INFORMATION PLEASE CONTACT: Investor Relations: Helix BioPharma Corp. Tel: 905 841-2300 Email: firstname.lastname@example.org
- Co-pilot spoke last words heard from missing Malaysian plane |
- U.S., EU impose sanctions after Crimea moves to join Russia |
- Crimeans vote over 90 percent to quit Ukraine for Russia |
- China rejects North Korean crimes report, hits chance of prosecution
- UPDATE 1-Rolls-Royce concurs with Malaysia on missing jet's engine data